Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

Clinical Infectious Diseases

Volumn 22, Issue 5, 1996, Pages 813-818

  Wenisch, C ^a   Parschalk, B ^b   Hasenhundl M ^b   Hirschl, A M ^b   Graninger, W ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FUSIDIC ACID; METRONIDAZOLE; TEICOPLANIN; VANCOMYCIN;

ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG EFFICACY; ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0030056217     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.5.813     Document Type: Article

References (25)

1. Knapp FC, Owens M, Crocker IC. Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev 1993;6:251-65.
2. Kelly CP, Pothulakis C, La Mont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
3. Fekety R, Silva R, Toshniwal R, et al. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis 1979;1:386-97.
4. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembraneous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992;36:2192-6.
5. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumarines B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35:1108-11.
6. Bavasco F, Manso E, Varaldo PE. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 1991;35:195-7.
7. Burdon DW, Broen JD, Younga DJ, et al. Antibiotic susceptibility of Clostridium difficile. J Antimicrob Chemother 1979;5:307-10.
8. Teasley DG, Olson MM, Gebhard RL, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhea and colitis. Lancet 1983;2:1043-6.
9. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15:371-81.
10. Eykyn SJ. Staphylococcal bacteraemia and endocarditis and fusidic acid. J Antimicrob Chemother 1990;25 (suppl B):33-8.
11. Coombs RRH. Fusidic acid in staphylococcal bone and joint infection. J Antimicrob Chemother 1990;25 (suppl B):53-60.
12. Nordin P, Mobacken H. A comparison of fusidic acid and flucloxacillin in the treatment of skin and soft tissue infection. Eur J Clin Res 1994;5:97-106.
13. Shanson DC. Clinical relevance of resistance to fusidic acid in Staphylococcus aureus. J Antimicrob Chemother 1990;25 (suppl B):15-21.
14. Cronberg S, Castor B, Thoren A. Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. Infection 1984;16:234-41.
15. Shanholtzer CJ, Peterson LR, Olson MM, Gerding DN. Prospective study of gram-stained stool smears. J Clin Microbiol 1983;17:906-8.
16. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-8.
17. Brown E, Talbot GH, Axelrod P, Provencher M, Hoegg C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect Control Hosp Epidemiol 1990;11:283-90.
18. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993;17: 109-13.
19. McKinley MJ, Troncale F, Sangree MH, Scholhamer C, Brand M. Antibiotic-associated colitis: clinical and epidemiological features. Am J Gastroenterology 1982;77:77-81.
20. Mulligan ME. Epidemiology of Clostridium difficile-induced intestinal disease. Rev Infect Dis 1984;6 (suppl 1):5222-8.
21. Greenfield C, Burroughs A, Szawathowski M, Bass N, Noone P, Pounder R. Is pseudomembranous colitis infectious? Lancet 1981; 1:371-2.
22. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. New Engl J Med 1989;320:204-10.
23. Goldstein EJC, Citron DM, Goldman RJ. National hospital survey of anaerobic culture and susceptibility testing methods: results and recommendations for improvement. J Clin Microbiol 1992;30: 1529-34.
24. Wenisch C, Etzersdorfer E, Breyer S, Graninger W. Intravenous teicoplanin does not prevent Clostridium difficile associated diarrhea. Clin Investig 1994;72:922-4.
25. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27:1169-72.